AHA Conference 2024 -  BROOKLYN: Safety and efficacy outcomes of obicetrapib (NewAmsterdam Pharma) alongside lipid-lowering therapy in Heterozygous Familial Hypercholesterolemia (HeFH) management.

Dr Stephen Nicholls (Monash University and The Victorian Heart Hospital, Melbourne, AU) joins us onsite at AHA Conference to discuss the findings from BROOKLYN (NCT05425745).

BROOKLYN is a phase 3, randomized, placebo-controlled trial investigating the use of obicetrapib in patients with HeFH who have undergone at least eight weeks of maximally tolerated lipid modifying therapy prior to screening. 354 patients were enrolled in the trial and were followed-up after the 365-day treatment period. The primary outcome measure was the percent change from baseline to day 84 in low density lipoprotein-cholesterol.

Interview Questions:
1.    What is the reasoning behind the trial and the current unmet needs in HeFH management?
2.    Could you tell us about the mechanism of action behind obicetrapib?
3.    What was the study design and patient population?
4.    What were the key findings?
5.    What further research is needed in this area?

Recorded on-site at AHA Conference in Chicago, 2024.

Editors: Yazmin Sadik, Jordan Rance.
Videographers: Mike Knight, Dan Brent, Oliver Miles, Tom Green, David Ben-Harosh.

Support: This is an independent interview produced by Radcliffe Cardiology.